Jidinum

Sitagliptin, the active ingredient in Jidinum, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is employed to improve glycemic control in adults with type 2 diabetes mellitus. It works by selectively inhibiting the dipeptidyl peptidase‑4 enzyme, thereby increasing endogenous incretin levels which stimulate insulin release and reduce glucagon secretion in a glucose‑dependent manner.

GNH USA supplies Jidinum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU market quality standards and providing reliable global distribution.

Sitagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance.

Type 2 diabetes mellitus: improves glycemic control when used with diet and exercise, alone or in combination with other antidiabetic agents.

Sitagliptin may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: inflammation of the nose and throat causing sore throat or runny nose. - Headache: mild to moderate head pain. - Upper respiratory tract infection: symptoms such as cough, congestion, or fever.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain, nausea, and vomiting indicating inflammation of the pancreas. - Severe allergic reactions: including angioedema, Stevens‑Johnson syndrome, or anaphylaxis. - Joint pain: unexplained arthralgia that may require medical evaluation.

When prescribing sitagliptin, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: monitor patients with a history of heart failure. - Concomitant hypoglycemic agents: risk of low blood sugar increases when combined with insulin or sulfonylureas. - Pancreatitis history: discontinue if signs of pancreatitis develop. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Sitagliptin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Insulin or sulfonylureas: combined use may cause significant hypoglycemia. - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce sitagliptin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may decrease sitagliptin effectiveness. - ACE inhibitors or ARBs: may increase risk of angioedema. - Anticoagulants (e.g., warfarin): monitor INR as sitagliptin may affect clotting parameters.